Deutsche Bank AG Acquires 19,308 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Deutsche Bank AG raised its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 45.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 61,771 shares of the medical device company's stock after purchasing an additional 19,308 shares during the quarter. Deutsche Bank AG owned 0.09% of Tandem Diabetes Care worth $2,225,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Hood River Capital Management LLC bought a new position in shares of Tandem Diabetes Care in the fourth quarter valued at approximately $46,035,000. Brown Advisory Inc. bought a new position in shares of Tandem Diabetes Care in the fourth quarter worth $32,889,000. Park West Asset Management LLC grew its stake in Tandem Diabetes Care by 49.5% during the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock valued at $57,632,000 after acquiring an additional 530,000 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in Tandem Diabetes Care by 235.7% in the 4th quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company's stock valued at $26,875,000 after purchasing an additional 523,843 shares during the period. Finally, ArrowMark Colorado Holdings LLC increased its stake in Tandem Diabetes Care by 14.1% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock worth $98,108,000 after acquiring an additional 337,026 shares during the last quarter.

Insider Activity

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of Tandem Diabetes Care stock in a transaction dated Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the acquisition, the chief operating officer now owns 10,538 shares of the company's stock, valued at $190,948.56. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.90% of the company's stock.

Tandem Diabetes Care Stock Performance

NASDAQ TNDM traded up $0.08 on Friday, hitting $20.72. 945,052 shares of the company traded hands, compared to its average volume of 1,487,297. Tandem Diabetes Care, Inc. has a 52-week low of $15.75 and a 52-week high of $53.69. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -10.74 and a beta of 1.47. The business's 50 day moving average price is $19.40 and its 200-day moving average price is $27.42.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $234.42 million for the quarter, compared to the consensus estimate of $220.19 million. During the same quarter in the previous year, the business earned ($0.65) EPS. The company's quarterly revenue was up 22.3% on a year-over-year basis. Equities analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

TNDM has been the subject of several research analyst reports. The Goldman Sachs Group dropped their target price on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Stifel Nicolaus lowered their price target on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Sanford C. Bernstein downgraded Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Wells Fargo & Company decreased their price objective on shares of Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 1st. Finally, Morgan Stanley cut Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $45.00 to $22.00 in a research note on Wednesday, March 5th. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $37.47.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.